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The response of tumour vasculature to angiotensm II revealed by its
systemic and local administration to 'tissue-isolated' tumours
GM Tozer and KM Shaffi
Microcirculation Group, Gray Laboratory Cancer Research Trust, PO Box 100, Mount Vernon Hospital, Northwood, Middlesex
HA6 2JR, UK.
Sumnman- A tissue-isolated preparation of the P22 rat carcinosarcoma was used to investigate the tumour
vascular response to angiotensin II (ATII). In particular. the relative importance of systemic and local tumour
factors was assessed by comparing tumour vascular resistance during systemic administration of ATII and
during administration directly into the tumour-supplying artery. The effect of hypervolaemia on tumour
vascular resistance was determined as well as the effect of ATII on oxygen metabolism. Tumour vascular
resistance was increased by ATII in a dose-dependent manner. The response was biphasic with an initial peak
in resistance followed by a lower plateau phase. Systemic administration of ATII was more effective in
increasing tumour vascular resistance than direct administration. This suggests that systemic administration is
not causing any reopening of previously collapsed tumour blood vessels. Further evidence for this is that
hypervolaemia caused no reduction in tumour vascular resistance and that there was no difference in oxygen
extraction by tumours between groups treated with systemically and directly administered ATII. A
heterogeneous distribution of ATII receptors in the P22 tumour is a more likely explanation for the known
heterogeneity of blood flow response to ATII.
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Intravenous infusion of angiotensin II (ATII) has been found
to increase tumour blood flow relative to most normal tis-
sues, and this has led to the concept of 'hypertension
chemotherapy'. in which ATII is used to improve the relative
delivery of chemotherapeutic agents to tumours (Susuki et
al., 1981; Takematsu et al.. 1985; Noguchi et al., 1988;
Kobayashi et al.. 1990. 1991; Anderson et al., 1991; Kerr et
al., 1992; Mutoh et al., 1992). However, in absolute terms,
ATII has been found to increase blood flow in some tumours
(Tokuda et al.. 1990; Honr et al., 1991; Tanda et al., 1991)
while decreasing it in others (Jirtle et al., 1978; Tozer and
Shaffi, 1993). A decrease in absolute tumour blood flow
could compromise delivery of drug to tumour microregions.
Whether tumour blood flow increases or decreases is depen-
dent upon the balance between drug-induced hypertension
ansing from systemic vasoconstriction and local vasoconstric-
tion induced within the tumour itself (since blood flow = per-
fusion pressure . vascular resistance). Presumably, this bal-
ance varies with tumour type. although the underlying fac-
tors which determine response remain unclear. It is important
to identify these factors in order to predict the response of a
particular tumour to ATII.
We have previously found that ATII causes a significant
increase in the vascular resistance of early generation, sub-
cutaneous transplants of the P22 rat carcinosarcoma (Tozer
and Shaffi, 1993; Tozer et al., 1994a). We also found that the
degree of vasoconstriction induced by ATII was dependent
on pretreatment blood flow. That is, in whole tumours,
vasoconstriction was greatest where blood flow to control
tumours was highest and, in tumour sections, ATII caused a
greater reduction in blood flow in the tumour periphery
(pretreatment blood flow relatively high) than in the tumour
centre (pretreatment blood flow relatively low). The cause of
this differential effect was not clear. We proposed that (1)
high-flow regions within tumours have a high density of
receptors for ATII and or (2) there are collapsed blood
vessels within low-flow tumour regions which reopen owing
to ATII-induced hypertension. This paper is concerned with
the second possibility.
The influence of hypertension on tumour blood vessel
patency was investigated using a 'tissue-isolated' tumour
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system in which drugs can be delivered to the tumour with-
out entry into the systemic circulation. This allowed for (1)
companson of the effects of systemic and local administra-
tion of ATII on tumour vascular resistance; (2) investigation
of the effect of hypervolaemia on tumour vascular resistance;
and (3) measurement of oxygen consumption and oxygen
extraction before and after systemic/direct administration of
ATII as an indicator of the perfused tumour fraction. A
complete time course of drug-induced vasoactivity was also
obtained via continuous monitoring of tumour blood flow
from the venous outflow.
Materials and methods
Tumours
A transplanted rat carcinosarcoma. designated P22, was used
for these experiments. Its origin and subcutaneous maint-
enance in BD9 rats have been described previously (Tozer
and Shaffi, 1993). Growth of the P22 tumour as a Itissue-
isolated' preparation in which the tumour microcirculation is
derived from a single artery and vein has also been described
previously (Tozer et al., 1994b) and is based on the method
first described by Gullino and Grantham (1961) and Gran-
tham et al. (1973). This type of model has subsequently been
used for characterising various aspects of the tumour mic-
rocirculation (Vaupel et al., 1985; Sevick and Jain, 1989a.b.
1991; Graham et al., 1991; Eskey et al., 1993). Briefly, early-
generation tumours growing subcutaneously in male BD9
rats were used as donors. Recipient male BD9 rats (9-11
weeks old) were anaesthetised with Hypnorm (Crown
Chemical) and midazolam (Roche) and donor tumour was
implanted into an isolated section (approximately 0.2 g) of
the right inguinal fat pad supplied by the proximal portion of
the epigastric artery and vein. Moulded silicon chambers
made from Silastic MDX4-4210 medical grade elastomer
(Dow Corning) were used to enclose the fat and growing
tumour and prevent ingrowth of new blood vessels from
surrounding normal tissues.
Surgical preparation
Two to three weeks after tumour implantation. when
tumours reached 0.6-1.3 g. animals were prepared for
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experimentation. This preparation has been descnrbed prev-
iously (Tozer et al.. 1994b). Briefly, animals were reanaes-
thetised with Hypnorm and midazolam and the right
saphenous artery and femoral vein catheterised. The femoral
artery and vein distal to the catheterisation site were ligated
and a piece of suture thread was placed under the femoral
vein proximal to the catheterisation site. All other vessels
nearby. including the saphenous vein and muscular artery
and vein, were ligated or cauterised. This arrangement per-
mits the administration of agents directly to the tumour via
the arterial catheter without their entry into the systemic
circulation and without interference of the normal blood
supply to the tumour. It also enables collection of venous
outflow from the tumour without disrupting its arterial sup-
ply. The tumour was kept warm and moist throughout the
surgical procedure. A tail artery and one or two tail veins
were also catheterised and the wounds strapped. The
preparation was left undisturbed for approximately half an
hour before further experimentation.
Isolation of tumour blood supply
After the rest period rats were heparinised by intravenous
bolus injection of 0.1 ml of heparin (1000 units ml-').
Venous drainage from the tumour was diverted from the
femoral vein to the venous catheter by tying off the suture
around the femoral vein and venous blood was collected
every 2 min into preweighed vials with the aid of a fraction
collector. Continuous monitoring of blood flow in ml mmn-'
was achieved by weighing each blood sample and using a
value of 1.05 for the density of whole blood. Blood volume
was maintained bv infusion of donor blood into a
catheterised tail vein at the same rate as the venous outflow
from the tumour (Tozer et al.. 1994b).
Once blood flow had stabilised. animals were either
administered ATII or blood volume was modified as des-
cribed below. Throughout these procedures tumour blood
flow was monitored continuously, every 2 min. from the
venous outflow. Systemic arterial blood pressure was con-
tinuously monitored via a pressure transducer (Gould) con-
nected to the tail arterx catheter. Arterial blood haematocrits
were measured before and during treatment using microcent-
rifugation of blood collected from the tail artery. Top-up
doses of anaesthetic were administered intraperitoneally at
regular intervals and rats were kept warm using a thermos-
taticallv controlled heating blanket and an angle-poise lamp.
Surface tumour temperature was monitored using a ther-
mocouple and maintained between 34.0 and 36.5°C through-
out the experimental period.
Administration of angiotensin II
Aliquots of angiotensin II. which had been made up to a
concentration of 200 jig ml-' in distilled deionised water and
stored at -20'C. were defrosted on each expenrmental day
and were suitably diluted in 0.9% saline for infusion.
Animals were designated for either systemic or local ATII
administration. ATII at a concentration of 2 jg ml-' was
infused into a catheterised tail vein for systemic administra-
tion. Dose rates from 10 to 1200 ng kg-' min-' were
obtained by varying the infusion rate between 5 jI kg-'
min and 600 1il kg-' min- '. ATII at a concentration of
0.5 jig ml- was infused into the cathetenrsed saphenous
artery for direct administration to the tumour. Dose rates
from 0.2 to 5.0 ng min-' were obtained by varying the
infusion rate between 0.4 ILI min'- and 10.0 jIl min-'. Direct
infusion rates never exceeded 10% of the total tumour blood
flow. These dose rate ranges were chosen to approximate
equivalent plasma concentrations of ATII for the two routes.
Our previous measurements of blood flow to tissue-isolated
tumours suggest that they receive approximately 0.6% of the
cardiac output (assumed to be 50 ml min') (Tozer et al..
1 994b). Thus. for the highest systemic dose rate used
(1200 ng kg-' min-') and a 350 g rat this is approximately
equivalent to 2.5 ng min-' ATII reaching the tumour which
is of the same order as the highest directly administered dose
rate.
ATII doses were increased in a stepwise manner for each
rat and blood flow was allowed to stabilise for at least
10 mmn at each dose before further modification. After
administration of the highest dose. ATII infusion was discon-
tinued and rats were sacrificed by bolus intravenous injection
of approximately 0.2 ml of Euthatal (RMB Animal Health).
Tumours were excised and weighed so that tumour blood
flow could be calculated as ml blood per g of tumour per
minute (ml g-' min-').
.Modification of blood l olume
Blood volume was increased in a stepwise manner for each
rat by increasing the infusion rate of the donor blood above
that of the venous outflow from the tumour. Infusion rate
was adjusted between 100% and 300% of the outflow so that
blood pressure gradually increased to approximately 130
mmHg over approximately 60 mn. This amounted to
5.3 ± 1.1 ml of donor blood added to the normal blood
volume. A tendency for hypervolaemia to induce a hae-
moconcentration was corrected by adding extra plasma fluid
to the donor blood. Rats were then sacrificed and tumours
excised as described above.
Oxygen measurements
Blood samples (approximately 0.2 ml) were occasionally
drawn from the catheterised tail artery or the venous outflow
from the tumour for measurement of oxygen levels before
and during the procedures described above. Blood sample
containers were sealed and stored on ice before measuring
oxygen partial pressure (po2) using a Corming 178 pH, 'blood
gas analyser (Corming Medical). Measurements were made
within 30 min of blood collection.
Oxygen concentration (co, in per cent) for each blood
sample was calculated from po2 (in kPa) using the
oxygen-haemoglobin dissociation curve for rat blood (Gray
and Steadman. 1964) and 9.24 mmol 1 ' for the oxygen-
carrying capacity of blood. Oxygen availability (Ao. in lil gl
mn 1) was calculated from co, of arterial blood and blood
flow measurements from the venous outflow. Oxygen con-
sumption (Qo in jil g-' min-') was calculated from the
difference in co, between arterial and venous blood draining
the tumour and blood flow measurements from the venous
outflow. The fraction of oxygen extracted from the arterial
blood as it passes through the tumour (oxygen extraction)
was calculated from Qon . Ao.
Anal ysis of results
Mean arterial blood pressure was considered to be equivalent
to the perfusion pressure of the tumour. ATII-induced
changes in tumour vascular tone were assessed by calculating
tumour vascular resistance from perfusion pressure . tumour
blood flow. Most results were expressed as percentage
changes in vascular resistance from a pretreatment control
value for each rat. The significance of differences between
means was tested using the Student's t-test for unpaired data
or analysis of variance.
Results
Absolute levels of mean arterial blood pressure, tumour
blood flow and tumour vascular resistance before (1)
modification using systemically administered ATII. (2)
modification using locally administered ATII and (3)
modification using hypervolaemia are shown in Table 1.
There was no significant difference between the three groups
for blood pressure or vascular resistance (analysis of
variance. P = 0.11 and 0.10 respectively). However, pretreat-
ment blood flow in the hypervolaemia group was significantly
higher than in the other two groups (analysis of variance.
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P = 0.05). For this reason the hypervolaemia group was exc-
luded from any between-group analyses of post-treatment
parameters.
Continuous monitoring of blood pressure detected no
obvious volume loading effects for systemic ATII. There was
also no significant difference between arterial blood haem-
atocrit measured before and during systemic administration
of ATII (0.42 ± 0.01 and 0.40 ± 0.01 respectively). Tumour
vascular resistance was increased by ATII in a dose-
dependent manner whether administered systemically or
locally. However. the response was biphasic with an initial
peak in resistance followed by a lower, plateau phase. The
biphasic pattern was most apparent at the higher doses used.
This is illustrated for local administration in Figure 1.
Systemic administration of ATII to BD9 rats induced a
dose-related rise in mean arterial blood pressure as reported
previously (Tozer and Shaffi. 1993). The increase in blood
pressure was accompanied by an increase in vascular resis-
tance in the tumours (Figure 2a), which was similar to that
found for the same tumours growing subcutaneously (Tozer
and Shaffi. 1993). Blood flow during the plateau phase of the
response was used for calculation of vascular resistance for
this purpose. The increase in flow resistance was sufficiently
large to overcome the tendency for tumour blood flow to
increase in response to the rise in perfusion pressure, and the
net result was a small decrease in tumour blood flow as
shown in Figure 2b. Again, this effect is similar to that found
for the subcutaneous site (Tozer and Shaffi, 1993).
Figure 3 shows the ATII-induced increase in plateau phase
tumour vascular resistance for direct (Figure 3a) and
systemic (Figure 3b) ATII administration, over roughly
equivalent dose rate ranges (see Materials and methods).
Local administration of ATII directly to the tumour induced
a dose-related increase in vascular resistance which saturated
at approximately 0.6 ng min-' (Figure 3a). Assuming that
ATII does not affect blood viscosity, this clearly illustrates a
direct vasoconstrictive effect of the drug in the P22 tumour.
On average, plateau phase vascular resistance could not be
increased above about 180% of the control level by locally
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administered ATII. Conversely. systemic administration of
ATII produced a dose-dependent increase in vascular resis-
tance which did not reach saturation at the doses used
(Figure 3b). Increases in plateau phase flow resistance above
250% were achieved via this route of administration.
Haematocrit dunrng hypervolaemia was 0.47 ± 0.02 com-
pared with 0.44 ± 0.01 before modification. Figure 4 shows
tumour vascular resistance vs perfusion pressure for rats in
which blood pressure was modified using hypervolaemia. The
effect of ATII-induced hypertension is also shown for com-
panson. There is no indication of any reduction in vascular
resistance as blood pressure is raised above normal levels.
Oxygen availability (Ao,) to tumours before ATII adminis-
tration ranged from 42 to 147 f.l g-' min-'. Despite this large
range. mean pretreatment Ao2 was similar in the two ATII
treatment groups (87 ± 15 p1 g' min-' for direct administra-
tion and 74 ± 21 1 g-1 min' for systemic administration).
During ATII administration, oxygen availability decreased as
blood flow declined. This was accompanied by an increase in
oxygen extraction and a tendency for oxygen consumption
(Qo.) rates to decrease (results not shown). Figure 5 shows
tumour Q02 and oxygen extraction before treatment (pooled
data), during systemic administration of ATII and during
administration directly to the tumour. Qo0 was not reduced
by ATII at the Ao. level chosen for analysis (see Figure 5
legend). Oxygen extraction was significantly increased by
ATII for both systemic and direct administration (Student's
t-test for unpaired data. P<0.05). However, the route of
administration made no difference to either Qo2 or oxygen
extraction (Student's t-test for unpaired data).
This study clearly demonstrates vasoconstriction of the P22
tumour in response to both systemically and locally
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Fire I Example of changes in tumour vascular resistance
induced by ATII administered directly to the tumour. Arrows
indicate start of continuous infusion of escalating doses of ATII
(0.15. 0.20. 0.40. 0.80. 1.5. 3.0 and 5.0ng min-').
Table 1 Comparison ofabsolute levels ofmean artenral blood pressure.
tumour blood flow and tumour vascular resistance before treatment
with systemic ATII. directly administered ATII or hypervolaemia
Pretreatment values
Mean arterial Vascular
blood pressure Bloodflow- resistance
Treatment (mmHg) (mlg ' min,') (res. units)
Systemic ATII 81.1 ± 3.6 0.40 ± 0.07 226 ± 20
Direct ATII 89.2 ± 4.0 0.48 ± 0.08 201 ± 22
Hypervolaemia 93.2 ±4.0 0.69 0.08 156 22
Errors are 1 s.e.m. Res. unit. (mmHgXml g-l min- ')-'.
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Fue 2 Effect of systemic administration of ATII on tumour
vascular resistance (a) and tumour blood flow (b). Errors are
r.m.s. values; n=6. Dose rates used were 10-1200ngkg-'
min-'. Lines are interpolated.
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Fire 3 Compan'son of the effects on tumour vascular resis-
tance of direct administration of ATII (a) and systemic administ-
ration of ATII (b). Errors are r.m.s. values; n = 5 for (a) and 6
for (b). The highest systemic dose rate is roughly equivalent to
the highest direct dose rate in terms of concentration reaching the
tumour (see Materials and methods for details). Lines are inter-
polated.
administered ATII. Theoretically, vasoconstriction following
systemic administration could result from autoregulation in
the tumour (an increase in flow resistance with increasing
perfusion pressure which maintains blood flow constant over
a large pressure range). However, local administration of
ATII unequivocally demonstrated a direct response of the
tumour blood vessels to the vasoconstrictive effects of the
polypeptide.
A previous study has shown that, for systemic administra-
tion tumour vasoconstriction is of a similar order to that
elicited in skeletal muscle and kidney (Tozer and Shaffi,
1993). It is now clear that tumour vasoconstriction is dose
dependent and that there is an initial peak in flow resistance
which decays to a plateau value after the first minute or so of
infusion. This biphasic response is a function of the local
response of the tumour, although it is also observed during
systemic administration. It implies that the effectiveness of
chemotherapeutic drug administration during ATII infusion
will be critically dependent upon timing. Recently, a similar
biphasic response has been reported for isolated perfusions of
the rabbit heart (Porsti et al., 1993). These authors found
that, at high ATII doses (> 10 nM), the flow resistance in
the plateau phase was lower than the initial flow resistance,
indicating vasodilatation. They concluded that the secondary
vasodilatation was independent of the two primary endo-
thelial autocoids, nitric oxide and prostacycin, and most
likely reflected a desensitisation of the coronary artenral
smooth muscle to the constrictor effect of ATII and an
accumulation of vasodilatory metabolites such as adenosine
during the constrictive phase. Desensitisation involves both
reduction in number of ATII receptors and post-receptor
mechanisms. Similar mechanisms are likely to be involved in
the tumour response.
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Fue 4 Effect of hypertension on tumour vascular resistance.
Open symbols (n = 6) show the effect of systemically administered
ATII; closed symbols (n = 5) show the effect of hypervolaemia.
Errors are r.m.s. values. Lines are interpolated.
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No evidence was found for any ATII-induced reopening of
previously collapsed tumour blood vessels which could ex-
plain our previous finding of a spatially heterogeneous
tumour response to ATII (Tozer and Shaffi, 1993; Tozer et
al., 1994a). The P22 tumour was grown subcutaneously in
that study rather than in the inguinal fat pad, and so we
cannot discount the possibility that the present results are
due to tissue isolation per se. However, the overall response
to ATII was similar in the two sites, indicating some
relevance of the inguinal tumours to the subcutaneous site.
The first piece of evidence against hypertension-induced
reopening of collapsed tumour vessels is that systemic
administration of ATII was more effective than local
administration in increasing vascular resistance in the P22
tumour. If hypertension associated with systemic administra-
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tion of ATII were causing any reopening of previously col-
lapsed vessels, this would tend to reduce the overall flow
resistance in the tumour not increase it. The most probable
explanation for our result is central stimulation of the sym-
pathetic nervous system under systemic administration of
ATII, possibly combined with enhancement of noradrenaline
release into the bloodstream from sympathetic nerve fibres.
These are both well-documented effects of exogenous ATII
(Phillips, 1987). There have been several reports of cate-
cholamine-induced vasoconstriction in other tumour systems
which make this a feasible explanation for our results (Weiss
et al., 1979, 1986; Tveit et al., 1987; Honr et al., 1993).
Secondly, hypervolaemia had no effect on tumour vascular
resistance despite significantly increasing mean arterial blood
pressure. A similar relationship between perfusion pressure
and flow resistance has been found for ex vivo perfusions of
the P22 tumour where systemic factors could not be involved
in the response (Sensky et al., 1993).
Thirdly, there was no difference between the effects of
systemic and direct administration of ATII on Qo, or oxygen
extraction at the same Ao. An increased oxygen extraction
might have been expected for systemic administration if the
associated hypertension had increased the perfused fraction
of the tumour via reopening of collapsed tumour blood
vessels. The oxygen consumption rate (Qo) of the P22 car-
cinosarcoma before treatment was very similar to values
previously reported for other rodent tumours and human
tumour xenografts grown as tissue-isolated preparations
(Gullino, 1976; Vaupel et al.. 1987). The increase in oxygen
extraction and the tendency for oxygen consumption to dec-
line during ATII administration was most likely a secondary
effect of the decreased blood flow and therefore oxygen
availability (Ao,) rather than a direct drug effect.
The use of anaesthesia is a possible artefact in these
experiments which cannot be avoided. However, it does not
preclude comparison of results with our earlier study in
which the same anaesthetic agent was used (Tozer and Shaffi.
1993: Tozer et al.. 1994a). In summary. we have found no
evidence to support the proposal that ATII induces reopen-
mg of collapsed tumour blood vessels (Trotter et al.. 1991:
Tozer and Shaffi, 1993: Tozer et al.. 1994a). Therefore.
poorly perfused tumour regions may still be a problem under
ATII-induced hypertension even when the mean absolute
tumour blood flow is increased. A more likely explanation
for our previous finding that ATII causes selective vasocons-
triction at the tumour periphery is a heterogeneous distnrbu-
tion of receptors for ATII. A study into this possibility is
now in progress. Differences in receptor number and subtype
between different tumour types are also a likely explanation
for the conflicting reports of ATII-induced blood flow
changes. We have found that the response of the P22 vas-
culature to ATII is biphasic. It is possible that in some
tumours with a different complement of ATII receptors. high
doses of ATII could actually cause vasodilatation via desen-
sitisation of the AT, receptor subtype and build-up of
adenosine, as has been described in the heart (Porsti et al..
1993). Finally, we have found that the overall response of the
tumour vasculature to systemically administered ATII is
determined by direct vasoconstriction of blood vessels supp-
lying the tumour and a further indirect vasoconstriction
which is most probably associated with sympathetic stimula-
tion. Pharmacological blockade of sympathetic stimulation in
combination with ATII administration may therefore provide
a means of reducing tumour vasoconstnrction and thus
eliciting an increase in tumour blood flow.
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